| |
Adimab
Avedro
Bar Harbor Biotechnology
GlycoFi
M2S |
Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology. |
 Adimab, Inc.
16 Cavendish Court
Lebanon, NH 03766
Initial Investment: November 2008
CEO: Tillman Gerngross |
|
